Fulcrum Therapeutics, Inc. filings document the regulatory record of a clinical-stage biopharmaceutical company focused on small-molecule therapies for genetically defined rare diseases and rare hematological disorders. Form 8-K reports cover operating results, financial condition, Regulation FD corporate presentations, clinical updates for pociredir in sickle cell disease, and material agreements, including license arrangements tied to development programs.
Proxy materials disclose board and governance matters, executive compensation, equity awards, shareholder voting items, and related ownership information. The filing record also documents capital-structure items such as common stock and inducement equity plans alongside public-company disclosures tied to drug development programs and collaboration agreements.
Fulcrum Therapeutics, Inc. Chief Legal Officer Curt Oltmans reported a small stock sale under a pre-arranged trading plan. On 12/15/2025, he sold 3,452 shares of Fulcrum Therapeutics common stock at a price of $12.92 per share, as shown in Table I of the filing.
The filing notes that these sales were made under a Rule 10b5-1 trading plan adopted on August 8, 2025, which is designed to follow preset instructions. After this transaction, Oltmans beneficially owned 10,252 shares, including shares previously acquired through the company’s employee stock purchase plan.
Fulcrum Therapeutics, Inc. entered into an underwriting agreement for an underwritten public offering of 11,851,853 shares of common stock at $13.50 per share and pre-funded warrants to purchase up to 1,111,193 shares of common stock at $13.499 per warrant. The underwriters also have a 30-day option to buy up to 1,944,456 additional shares at the same price, less underwriting discounts and commissions.
All securities are being sold by Fulcrum, which expects to receive net proceeds of about $164.1 million, or about $188.1 million if the underwriters fully exercise their option, after fees and expenses. The pre-funded warrants have a $0.001 exercise price, are immediately exercisable, and include ownership limits generally capped at 19.99% of outstanding common stock and additional limits tied to Hart-Scott-Rodino antitrust thresholds.
The offering is being made under an effective shelf registration statement, with closing expected on or about December 11, 2025, subject to customary conditions. Fulcrum and its directors and executive officers have agreed to short lock-up periods restricting additional sales of common stock following pricing.
Fulcrum Therapeutics director reports sale of common stock under trading plan. A reporting person serving as a director of Fulcrum Therapeutics, Inc. (FULC) sold 15,000 shares of common stock on 11/19/2025 in an open market transaction at a weighted average price of $11.033 per share. After this sale, the individual beneficially owns 484,864 shares of Fulcrum common stock in direct form. The transactions were carried out under a pre-arranged Rule 10b5-1 trading plan that was adopted on August 1, 2025, which is intended to allow systematic selling according to preset instructions.
Fulcrum Therapeutics (FULC) filed its Q3 2025 10‑Q, reporting continued operating focus on sickle cell candidate pociredir alongside tighter expenses. The quarter showed a net loss of $19.6 million on operating expenses of $21.9 million (R&D $14.3 million; G&A $7.6 million). Cash, cash equivalents, and marketable securities totaled $200.6 million as of September 30, 2025, and management states this should fund operations for at least 12 months from issuance. The accumulated deficit was $573.9 million.
Clinical update: In the 12 mg Phase 1b cohort (n=16), pociredir increased mean absolute fetal hemoglobin (HbF) by 8.6% at 12 weeks (7.6% to 16.2%); 7 of 16 exceeded 20% HbF. Hemolysis markers improved and mean hemoglobin rose by 0.9 g/dL. Safety was generally well-tolerated with no drug‑related serious adverse events or discontinuations. Enrollment in the 20 mg cohort (n=12) is complete, with data expected by the end of 2025.
There was no collaboration revenue in Q3 2025 (vs. $80.0 million in the first nine months of 2024 from a now-terminated Sanofi agreement). Shares outstanding were 54,118,438 as of October 22, 2025.
Fulcrum Therapeutics (FULC) filed an 8-K stating it announced financial results for the quarter ended September 30, 2025. A detailed press release was furnished as Exhibit 99.1 and incorporated by reference. The Item 2.02 information, including the exhibit, is furnished and not deemed filed under the Exchange Act. Fulcrum’s common stock trades on the Nasdaq Global Market under the symbol FULC.
Fulcrum Therapeutics, Inc. furnished an updated corporate presentation dated August 28, 2025 that may be used at conferences and investor meetings. The presentation is available in the Events and Presentations section of the company’s website and is attached as Exhibit 99.1. Fulcrum specifies that this material is provided under Regulation FD and is considered “furnished” rather than “filed,” which means it is not automatically subject to certain Exchange Act liabilities or incorporated into other securities law filings unless specifically referenced.
Adage Capital Management, L.P., together with Robert Atchinson and Phillip Gross, reports shared beneficial ownership of 4,589,000 shares of Fulcrum Therapeutics common stock, representing 8.50% of the class based on 53,979,306 shares outstanding. The shares are held directly by Adage Capital Partners, L.P., with Adage acting as investment manager and Messrs. Atchinson and Gross identified as managing members of the related entities.
The filing shows no sole voting or dispositive power; all voting and disposition power is reported as shared. The reporting persons certify the holdings are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.